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Summary
Leigh disease associated with cytochrome c oxidase de-
ficiency (LD[COX]) is one of the most common disorders
of the mitochondrial respiratory chain, in infancy and
childhood. No mutations in any of the genes encoding
the COX-protein subunits have been identified in
LD(COX) patients. Using complementation assays based
on the fusion of LD(COX) cell lines with several rodent/
human rho0 hybrids, we demonstrated that the COX
phenotype was rescued by the presence of a normal hu-
man chromosome 9. Linkage analysis restricted the dis-
ease locus to the subtelomeric region of chromosome 9q,
within the 7-cM interval between markers D9S1847 and
D9S1826. Candidate genes within this region include
SURF-1, the yeast homologue (SHY-1) of which encodes
a mitochondrial protein necessary for the maintenance
of COX activity and respiration. Sequence analysis of
SURF-1 revealed mutations in numerous DNA samples
from LD(COX) patients, indicating that this gene is re-
sponsible for the major complementation group in this
important mitochondrial disorder.
Introduction
Subacute necrotizing encephalomyelopathy, also known
as “Leigh disease” (LD; MIM 256000), is one of the
most common disorders of the respiratory chain, in in-
fancy and childhood. Biochemically, a generalized defect
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of respiratory complex IV (cytochrome c oxidase
[COX]) was found in the majority of our patients (Zev-
iani et al. 1996), although deficiencies of the pyruvate
dehydrogenase complex, respiratory complexes I (Rah-
man et al. 1996) or II (Bourgeron et al. 1995), and
mtDNA point mutations (Santorelli et al. 1993) have
been reported by others.
COX (E.C.1.9.3.1), the terminal component of the
mitochondrial respiratory chain, is a multiheteromeric
enzyme embedded in the mitochondrial inner mem-
brane. This complex consists of a protein backbone
bound to two copper-containing prosthetic groups, the
cytochromes a and a3 (Babcock and Wikstro¨m 1992).
Human COX is composed of 13 subunits: the 3 largest
are encoded by mtDNA genes, whereas the remaining
subunits are encoded by nuclear genes (Taanman 1997).
The sequences of the genes encoding all the COX sub-
units have been determined completely in humans (An-
derson et al. 1981; Grossman and Lomax 1997). No
mutations in any of the COX-encoding nuclear genes
have been found in patients with COX deficiency (Jaksch
et al. 1998).
We have demonstrated previously that most cases of
LD associated with COX deficiency (LD[COX]) belong
to one complementation group (Munaro et al. 1997).
However, at least two additional complementation
groups have been identified (Brown and Brown 1996;
V. Tiranti, C. Galimberti, and M. Zeviani, unpublished
data). Whether these complementation groups are the
result of mutations in different genes or whether they
represent allelic variants of the same gene is still unclear.
To identify an LD(COX) locus, we set up a three-step
strategy. First, we determined that most of the human
autosome does not contain the disease locus, by using
complementation of two LD(COX) cell lines, belonging
to the same complementation group, with several ro-
dent/human hybrids containing either single human
chromosomes or panels of different human chromo-
somes. Before fusion, the rodent/human hybrids were
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made rho0 (i.e., were deprived of their own mtDNA) by
prolonged exposure to high doses of ethidium bromide
(EtBr). Complementation of the COX defect was ob-
tained only with rodent/human rho0 hybrids that con-
tained human chromosome 9. In the second step, linkage
analysis of nine LD(COX) families belonging to the same
COX complementation group narrowed the critical re-
gion for an LD(COX) locus to a 7-cM interval on chro-
mosome 9q34.
Finally, we performed a mutation analysis of candi-
date genes, including the endonuclease G (ENDOG),
matrix-processing protease (MPP), and surfeit-1 (SURF-
1) genes. The latter is the human analogue of SHY-1, a
yeast gene whose product is targeted to mitochondria
and whose mutations impair mitochondrial respiration
(Mashkevich et al. 1997). SURF-1 was mutated in the
probands of nine LD(COX) families; in the probands of
six families, loss-of-function mutations were found on
both alleles.
Patients, Material, and Methods
Patients and Clinical Criteria for Inclusion
We studied 11 patients, belonging to nine families,
some of whom were described in an earlier report (Mu-
naro et al. 1997). All patients shared an apparently iden-
tical, rapidly progressive encephalopathy, characterized
by the following features: early onset; generalized hy-
potonia with brisk tendon reflexes; truncal ataxia;
oculomotor abnormalities, including slow saccades,
ophthalmoparesis, or complex irregular eye movements;
“central” abnormalities of ventilation, including epi-
sodes of apnea and irregular hyperpnea; and rapidly pro-
gressive psychomotor regression, leading to death from
central ventilatory failure. For all patients, a computed-
tomography scan or magnetic-resonance imaging re-
vealed the presence of symmetric lesions scattered from
the basal ganglia to the brain stem, including the cere-
bellum. In one case (the affected individual in family D),
necropsy examination showed the presence of necrotic
lesions associated with glial and vascular proliferation,
as is typically described in subacute necrotizing en-
cephalomyelopathy.
Biochemically, lactic acid in blood and urine was
above normal range, and a muscle-biopsy examination
showed a severe decrease of the histochemical reaction
to COX. Ragged-red fibers consistently were absent in
all cases. An isolated defect of COX (5%–10% of nor-
mal values) was detected in fibroblasts and muscle ho-
mogenates from all patients.
Cell Lines, Rodent/Human Hybrids, and Creation of
rho0 Derivatives
The recombinant plasmid pBABE40 was created by
insertion of an origin-defective SV40 genome excised by
EcoRI digestion of plasmid pRNS (Tiranti et al. 1995)
into plasmid pBABE, a vector expressing the gene con-
ferring resistance to puromycin (Munaro et al. 1997).
Therefore, pBABE40 expresses both the transformant
activity of the SV40 genome and resistance to puro-
mycin. The pBABE40 recombinant plasmid was stably
transfected (Tiranti et al. 1995) into two COX-defective
fibroblast cell lines from LD(COX) patients belonging to
the same complementation group (subjects S and M,
described by Munaro et al. [1997]) and into a COX-
positive fibroblast cell line from a normal individual
(subject A). The COX-defective transformant cell lines
were called “SpBABE40” and “MpBABE40,” and the
COX-positive control transformant cell line was called
“ApBABE40.”
The following monochromosomal hybrids (Coriell
Cell Repository) were used in the experiments:
GM13139 (containing human chromosome 1),
GM11712 (chromosome 2), GM11713 (chromosome
3), GM11714 (chromosome 5), GM10611A (chromo-
some 9), GM11688 (chromosome 10), GM11689 (chro-
mosome 13), and GM13260 (chromosome 20).
GM10611A is a hamster/human somatic cell hybrid in
which the human chromosome 9 expresses a gene con-
ferring resistance to histidinol, a reversible inhibitor of
protein synthesis. The other hybrids listed above are
mouse/human hybrids in which each human chromo-
some expresses the gene conferring resistance to neo-
mycin. Somatic hamster/human cell hybrids Y.XY.8F6,
HY.166T4, and HY.137J have been described elsewhere
(Rocchi et al. 1986). For some experiments, the mouse
L929 cell line and the hamster B14150 cell line were
also used.
All the somatic cell hybrids, as well as the mouse L929
and hamster B14150 cell lines, were exposed continu-
ously to 5 mg EtBr/ml in a rho0-permissive medium (Dul-
becco’s modified Eagle’s medium [DMEM]/uridine; see
“Fusion Procedure and Cell Cultures”) for 8–12 wk,
until the complete absence of endogenous mtDNA (and
mitochondrial OXPHOS) was proved for each of them.
The presence or absence of mouse or hamster mtDNA
was tested periodically by PCR amplification of species-
specific mtDNA sequences. The test sequences were as
follows: (1) a fragment in the human mtDNA D-loop,
spanning nucleotides (nts) 16130–500 (Anderson et al.
1981); (2) a fragment in the mouse mtDNA D-loop,
spanning nts 15431–16281 (Bibb et al. 1981); and (3)
a portion of the ATPase 6–URFA6L genes of hamster
mtDNA, spanning nts 60–767 (Breen et al. 1986). The
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rho0 derivatives were named by addition of the suffix
“r0” to the corresponding cell lines.
Cytogenetic Analysis
The human-chromosome content of the EtBr-treated
hybrids was assessed by reverse FISH. In brief, DNA
extracted from the hybrids was dual Alu-PCR amplified,
as described elsewhere (Liu et al. 1993). The PCR prod-
ucts were biotin labeled by nick translation and were
used as a probe for FISH experiments on normal human
metaphases obtained from phytohemagglutinin-stimu-
lated peripheral blood lymphocytes. In some instances,
the human-chromosome content was also checked, by
hybridization of biotin-labeled total human DNA on
metaphases obtained from the hybrid. In all FISH ex-
periments, chromosome identification was obtained by
diamidino-phenylindole (DAPI) counterstaining. The
presence of chromosome 9 in interphase nuclei from pa-
rental cells and from fused cells was screened by FISH
experiments using the alphoid probe pMR9A, which
specifically recognizes the centromeric region of chro-
mosome 9 (Rocchi et al. 1991). FISH experiments were
performed essentially as described elsewhere (Lichter et
al. 1990).
Digital images were obtained by use of a Leica epi-
fluorescence microscope (model DMRXA) equipped
with a cooled charge-coupled device (Princeton Instru-
ments). Cy3 (Amersham) and DAPI fluorescence signals,
detected with specific filters, were recorded separately as
gray-scale images. Pseudocoloring and merging of im-
ages were performed by use of Adobe Photoshop com-
mercial software.
Fusion Procedure and Cell Cultures
Approximately cells from the fibroblast cell60.5# 10
lines SpBABE40, MpBABE40, or ApBABE40 were co-
cultured with cells from each rho0 cell deriv-60.5# 10
ative, in a rho0-permissive medium composed of DMEM
containing 4.5 g glucose/liter and 110 mg pyruvate/ml,
supplemented with 5% fetal bovine serum (Boehringer)
and 50 mg uridine/ml (DMEM/uridine). After incubation
for 1 d, fusion was performed by treatment of the con-
fluent cell monolayer with a 50% (weight/volume) so-
lution of polyethylene-glycol (PEG) in a phosphate buf-
fer, pH 7.4. Twenty-four hours after fusion, cells were
trypsinized and replated in a uridine-less DMEM me-
dium containing 0.5 mg puromycin/ml, to select against
the unfused, puromycin-sensitive rho0 cell derivatives.
Selection against the unfused parental fibroblast cell lines
was performed by addition of 200 mg/ml of the neomycin
analogue drug G418, for the fusions with human/mouse
monochromosome rho0 hybrids expressing the neomy-
cin-resistance gene, or of 7 mM histidinol, for the fusions
with histidinol-resistant human/hamster monochromo-
some 9–specific GM10611A-r0. The histochemical and
biochemical assays were performed 3–4 d after fusion
and were repeated after at least 2 wk of continuous
selection.
Cytochemical and Biochemical Assays
COX activity was visualized cytochemically in cell cul-
tures grown on coverslips, as described elsewhere (Tir-
anti et al. 1995). Cell homogenates were prepared in
accordance with the digitonin-based method described
by Robinson et al. (1986), modified as described by Tir-
anti et al. (1995). The enzyme activities of COX were
measured twice in each assay (Darley-Usmar et al. 1987).
Protein concentration was measured by the method of
Lowry et al. (1951). Activities were expressed as na-
nomoles of substrate/min/mg protein. We did not nor-
malize the respiratory-chain activities for citrate syn-
thase, because citrate synthase is also expressed at high
levels in the rho0 mitochondria. This could have under-
estimated the respiratory activities in the rho0-derived
hybrids.
Linkage Analysis
Informed consent was obtained from the parents and
the adult sibs of the probands of seven families. The
members of two families could not be reached, and the
analysis was performed by use of genomic DNA ex-
tracted from fibroblast cell lines stored in our laboratory.
A disease frequency of 1/100,000, which accounts for
the rarity of LD(COX), and an autosomal recessive pat-
tern of inheritance were considered in the linkage anal-
ysis. The fluorescent oligonucleotide primers of the ABI
Prism Linkage Mapping Set (Applied Biosystems) were
used to PCR amplify a panel of 14 microsatellite markers
regularly distributed along human chromosome 9; the
order of the markers is as follows: pter–D9S288–
D9S286–D9S157–D9S171–D9S161–D9S273–D9S175
–D9S167–D9S283–D9S287–D9S279–D9S1831–
D9S164–D9S1826–qter. A second run of PCR amplifi-
cations using fluorescent oligonucleotides as primers was
performed to analyze three additional microsatellite
markers (D9S1847, D9S1793, and D9S1818) in the sub-
telomeric region of chromosome 9q. The genetic inter-
marker distances and the order of markers on chro-
mosome 9 were based on published information.
Microsatellites were PCR amplified by following the in-
struction manual of the ABI Prism Linkage Mapping Set
(version 2) and were analyzed in an ABI-377 automated
sequencer, by use of the GENESCAN and GENOTYPER
software packages (Applied Biosystems). The linkage
analyses were performed by use of the MLINK and IL-
INK options of the LINKAGE program package (version
5.1; Lathrop et al. 1984). The test for heterogeneity was
performed by use of the pairwise LOD scores for each
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Figure 1 PCR-based detection of mtDNA. Lane 1, Mouse-spe-
cific mtDNA fragment amplified from mouse L929 cells. Lane 2, Same
fragment as in lane 1. No amplification was obtained from an L929-
r0 derivative. Lane 3, Hamster-specific mtDNA fragment amplified
from hamster B14150 cells. Lane 4, Same fragment as in lane 3. No
amplification was obtained from a B14150-r0 derivative. Lane 5, Ham-
ster-specific mtDNA fragment amplified from chromosome 9–con-
taining GM10611A. Lane 6, Same fragment as in lane 5. No ampli-
fication was obtained from a GM10611A-r0 derivative. Lane 7,
Hamster mtDNA fragment. No amplification was obtained from a
SpBABE40  GM10611A-r0 fusion. Lane 8, Human-specific mtDNA
fragment amplified from an SpBABE40 cell line. Lane 9, Same frag-
ment as in lane 8, amplified from an SpBABE40  GM10611A-r0
fusion.
Table 1
Primers for PCR Amplification of Exons 1–9 of SURF-1
Exon(s) Oligonucleotide Sequences
Fragment Size
(bp) PCR Cycle
1 and 2a Sense: 5′-ATGCAGATGCTTCCTGCGTC-3′;
Antisense: 5′-CAGACAGCAGGTGGCTCTGC-3′
297 94C, 1 min; 56C, 1 min; 72C, 1 min
3 and 4 Sense: 5′-TTCGAGGGCTTCTGGCTCCA-3′;
Antisense: 5′-AAGTAAAACAGGCCCTAGG-3′
380 94C, 45 s; 60C, 1 min; 72C, 45 s
5 Sense: 5′-CAAACCTTGCTCGGCCACTG-3′;
Antisense: 5′-TCTGCCAGGACAGCCAGCTC-3′
275 94C, 45 s; 64C, 1 min; 72C, 45 s
6 and 7 Sense: 5′-CCACCTGAAGTAGCACTTTC-3′;
Antisense: 5′-AGCTACTTGTTCCGAGATGG-3′
389 94C, 45 s; 52C, 1 min; 72C, 45 s
8 and 9 Sense: 5′-AGAGGCTGGCAGGCCAGTAG-3′;
Antisense: 5′-CTGCATTATCCAGGGACAGGG-3′
318 94C, 45 s; 60C, 1 min; 72C, 45 s
a For PCR amplification, the following buffer was used (final concentration): 50 mM KCl; 20 mM Tris-HCl, pH 8.4;
3.5% formamide; 2 mM MgCl2; and 12% glycerol.
family as an input file for the HOMOG program (version
3.37; Ott 1991).
Identification of Candidate Genes and Sequence
Analysis
The database MITOP was used to identify mapped
expressed sequence tags (ESTs) and genes encoding pu-
tative mitochondrial proteins. MITOP presently includes
two categories of human mitochondrial genes with given
map positions: (1) mapped Unigene clusters of ESTs ho-
mologous to yeast mitochondrial genes and (2) mapped
genes encoding mammalian mitochondrial proteins.
The MITOP tool “human ESTs,” which is included
in each individual entry of yeast proteins, provided a list
of the best human-EST hits. A graphical alignment of
EST clusters to the related yeast reference sequence and
hyperlinks to Unigene helped to identify mapped EST
clusters. The tool MITOPROT, a software package de-
veloped for the characterization of mitochondrial pro-
teins (Claros 1995), was used to find mitochondrial tar-
geting sequences and to calculate the probability of the
import of proteins into mitochondria.
ENDOG and MPP cDNAs were amplified by reverse-
transcription PCR (cDNA cycle kit, Invitrogen) from to-
tal RNA extracted from the cells of two patients and
were sequenced with both sense and antisense primers.
The nine exons of the SURF-1 gene were amplified from
genomic DNA, by use of intronic primers (table 1). Both
forward and reverse sequences were analyzed by use of
an automated ABI-377 PRISM sequencer.
Results
Creation of Rodent and Rodent/Human rho0 Cell Lines
Prolonged exposure to 5 mg EtBr/ml, a concentration
100-fold higher than that used to produce human rho0
cells, resulted in the progressive elimination of endoge-
nous mtDNA in our rodent cell lines and human/rodent
somatic cell hybrids. In order to maintain the human
chromosomes during the EtBr treatment, the somatic cell
hybrids containing single human chromosomes were cul-
tured in the presence of either G418 (a neomycin ana-
logue) or histidinol, in accordance with the specific re-
sistance expressed by the human chromosome contained
in the hybrid (see Patients, Material, and Methods).
Neither rodent nor human mtDNA was detected, by
PCR, in any of the rho0 cell lines after cessation of treat-
ment with EtBr. An example of these results is shown
in figure 1. As expected, COX activity was absent as
well; examples of these results are shown in figures 2
and 3.
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Figure 3 COX-specific activities in different cell lines (see
Results).
The presence of the specific human chromosomes in
each of the rho0 rodent/human cell lines obtained after
EtBr treatment was investigated by reverse FISH. Ex-
amples of the results of these experiments are shown in
figure 4A–C. In addition, we prepared three rodent/hu-
man rho0 hybrids containing different sets of human
chromosomes in a hamster nuclear background (hybrids
Y.XY.8F6-r0, HY.166T4-r0, and HY.137J-r0). After EtBr
treatment, these hybrids retained human chromosomes
X, 3–7, 10–12, 17, 19, and 22 (Y.XY.8F6-r0); 7 and
21 (HY.166T4-r0); and 12, 20, 22, and the fragment
11p11.2-11q14 (HY.137J-r0). Examples of these results
are shown in figure 4D and E. Identification of the hu-
man-chromosome content in these hybrids was achieved
by means of molecular cytogenetic approaches, the re-
sults of which are shown in figure 4, or by means of
direct analysis by Q banding (data not shown).
COX-Complementation Assays
The mouse L929-r0 cell line lacked COX activity (fig.
2a). Identical results were obtained for all the rodent/
human rho0 cell lines, as well as for the hamster B14150-
r0 cell line (not shown). As shown in figure 2e, a hybrid
obtained by fusion of the mouse L929-r0 cell line (fig.
2a) with an LD(COX) patient’s transformant cell line (fig.
2d), called “SpBABE40,” did not rescue the COX phe-
notype, indicating that the rodent nuclear background
was unable to complement the human COX defect. By
contrast, a hybrid obtained by fusion of the same mouse
L929-r0 cell line with ApBABE40 (fig. 2b), a human
puromycin-resistant control transformant fibroblast cell
line, displayed a normal immunocytochemical reactivity
to COX (fig. 2f), indicating that the heterologous cell
fusion did not inhibit the activity of the enzyme. These
results were obtained consistently in several independent
experiments, by use of different conditions and cell lines
(including the hamster B14150-r0 cell line). On the basis
of these findings, we concluded that the rodent back-
ground did not interfere with the expression of the COX
phenotype, at least during the period of our observations
(up to 3 wk after fusion); therefore, this system could
be used to identify the human chromosome containing
a disease-complementing locus.
We then performed a series of PEG fusions between
the LD(COX) SpBABE40 cell line and each of our rodent/
human rho0 hybrid derivatives. No histochemical evi-
dence of COX complementation was obtained for the
rho0 hybrid derivatives containing the single human
chromosomes 1–3, 5, 10, 13, and 20. Likewise, no
complementation was detected in fusions between
SpBABE40 and the human/hamster hybrids Y.XY.8F6-
r0, HY.166T4-r0, and HY.137J-r0, which together con-
tained human chromosomes X, 3–7, 10–12, 17, 19,
20–22, and the fragment 11p11.2-11q14. From this
work, we concluded that most of the human genome
did not contain a gene complementing the COX defect
in our cell line. Fusion of the LD(COX) SpBABE40 cell
line with the hamster/human somatic cell rho0 derivative
GM10611A-r0 (fig. 2c), which contained chromosome
9 as the only human contribution, did show the presence
of numerous COX-positive cells as early as 4 d after
fusion (fig. 2g), indicating complementation of the COX
defect. A more generalized positive COX reaction was
obtained after a 2-wk selection of the same fusion, by
use of puromycin and histidinol in a uridine-less medium
(fig. 2h). The same results were obtained in two addi-
tional fusion experiments, by use of either SpBABE40
or another LD(COX) cell line (MpBABE40, see Patients,
Material, and Methods) as the proband cell line and of
GM10611A-r0 as the chromosome 9–donor cell line
(data not shown). Reverse FISH of hybrids Y.XY.8F6-
r0, HY.166T4-r0, and HY.137J-r0 (as well as of the cor-
responding rho progenitors) did not show the presence
of chromosome 9.
Functional complementation was verified by mea-
surement of COX-specific activity in cell homogenates
from the different fusions (fig. 3). A 4–5-fold increase
in COX activity was obtained in all the several
SpBABE40  GM10611A-r0 fusions, as compared with
the activity in SpBABE40 alone and that in the SpBABE
 L929-r0 fusion. The COX activity in the SpBABE40
 GM10611A-r0 fusions corresponded to ∼50% of the
normal mean. No increase of COX activity was detected
in any of the other fusions that were tested (data not
shown). The partial restoration of COX activity prob-
ably is due to incomplete selection of COX-defective
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Figure 5 FISH of GM10611A-r0  SpBABE40 fusions (chro-
mosome 9–containing r0 hybrid LD(COX) cell line), using the alphoid
probe pMR9A, which specifically recognizes the centromeric region
of chromosome 9. The presence of the three positive signals in the
two nuclei on the left identifies the corresponding cells as GM10611A-
r0  SpBABE40 fusion cells, whereas the presence of the two signals
in the nucleus on the right identifies the corresponding cell as an un-
fused SpBABE40 parental cell.
Figure 4 A–C, Examples of reverse FISH of monochromosomal hybrids GM11714, GM11688, and GM11689, retaining chromosomes
5, 10, and 13, respectively. D, Reverse-FISH characterization of hybrid HY.137J. E, FISH of metaphases from hybrid Y.XY.8F6, using total
human DNA as a probe.
parental cells or to a gene-dosage effect, since only one
of three copies of the LD(COX) gene should be function-
ally active in fusion cells. The presence of three chro-
mosomes 9 in the GM10611A-r0  SpBABE40 fusion
was confirmed by FISH on interphase chromosomes, by
using a human chromosome 9–specific alphoid DNA
sequence as a probe (fig. 5).
Assignment of the LD(COX) Locus on Chromosome
9q34, by Linkage Analysis
For the linkage analysis, we studied nine LD(COX) fam-
ilies (fig. 6) that all belonged to a single cell-comple-
mentation group (Munaro et al. 1997). Inheritance of
the trait was compatible or consistent with an autosomal
recessive pattern. Linkage analysis with a series of reg-
ularly interspersed chromosome 9–specific microsatellite
markers, separated from each other by a genetic distance
of ∼10 cM, excluded from linkage most of chromosome
9. Primary evidence for linkage was obtained with
marker D9S164 on 9q34 (table 2). Further characteri-
zation of the region was then performed with a panel
of consecutive microsatellite markers arranged in
the following order: cen–D9S287–D9S1831–D9S1847–
D9S1793–D9S164–D9S1818–D9S1826–tel (see fig. 6).
The results of cumulative pairwise analysis using these
markers, for nine families, are shown in table 2. MLINK
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Figure 6 Family pedigrees. Blackened symbols indicate subjects with LD(COX), and unblackened symbols indicate clinically healthy
individuals. Below each symbol is shown the individual haplotype covering a 48-cM region on chromosome 9q22-34. The markers from which
the haplotypes were constructed and their genetic distances are shown against a chromosome 9 idiotype. The boxed areas indicate the hap-
loidentical regions in affected individuals in families A and B, which define the critical LD(COX) region, between flanking markers D9S1847
and D9S1826.
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Table 2
Pairwise LOD Scores for Linkage of Chromosome 9q Markers with
LD(COX)
MARKER
LOD SCORE AT v 
Zmax v.00 .01 .05 .1 .2 .3 .4
D9S287        ) )
D9S1831  3.20 .86 .16 .15 .13 .05 1.64 .22
D9S1847  2.23 2.41 2.09 1.29 .63 .22 2.45 .03
D9S1793 4.03 3.90 3.36 2.73 1.61 .77 .25 4.06 .00
D9S164 4.32 4.18 3.60 2.91 1.70 .79 .25 4.32 .00
D9S1818 3.34 3.22 2.76 2.21 1.28 .60 .20 3.34 .00
D9S1826 3.65 .51 .53 .71 .56 .29 .09 .71 .10
analysis of the three consecutive markers D9S1793,
D9S164, and D9S1818 gave LOD scores 13 at a recom-
bination fraction (v) of .00. A maximum LOD score
(Zmax) of 4.32, calculated by use of the ILINK program,
was obtained for marker D9S164, at . As wasv  .00
expected, the affected members of the three consan-
guineous families shown in figure 6 were homozygous
for consecutive microsatellite markers within the critical
region. When the pairwise LOD scores of the closely
linked markers in the nine families were tested for het-
erogeneity (Ott 1991), the P value in favor of true locus
homogeneity was !.00001 ( , ).2x  19.940 df  1
As shown in figure 6, the haplotype reconstruction
demonstrated that in one of the two affected siblings
from family B a recombination had occurred in the
2-cM region between the most centromeric marker,
D9S1847, and adjacent marker D9S1793, whereas the
two siblings were haploidentical from D9S1793 to
D9S1826. Likewise, the two affected members of con-
sanguineous family A were haploidentical and homo-
zygous from D9S1818 to D9S1831 but showed different
alleles for the most telomeric marker, D9S1826. These
findings suggest that the critical region is located be-
tween D9S1847 and D9S1826, a distance of ∼7 cM.
Analysis of Candidate Genes and Mutation Detection
in SURF-1
The possible candidate genes identified, by MITOP,
in the critical region included ENDOG, MPP, and SURF-
1. No mutations were found by screening of the cDNA
sequences of ENDOG and MPP, in the two index pa-
tients from families F and G.
Alignment of the SURF-1 mRNA sequence (GenBank
accession number Z35093) with the genomic sequence
of cosmid 3H6 (GenBank AC0022107) showed nine ex-
ons, which spanned a genomic sequence of 5 kb. SURF-
1 exons 1–9 were amplified with intronic primers, and
homozygous and heterozygous mutations were detected
in all the patients, by sequencing of PCR products (fig.
7 and table 3). We found one splice-site mutation
(5162TrG), at the donor site of intron 5, in one allele
of both patients from family B and a homozygous mis-
sense mutation (751CrT), which converts the codon for
glutamine 251 into a stop codon (Q251X), in family G.
All the other mutations were insertions, deletions, or
deletions/insertions resulting in frameshifts. In particu-
lar, a frameshift homozygous duplication (37ins17) of a
17-bp sequence (5′-TTGCAGCTGGGGCTGCG-3′) was
found in exon 1 of both patients from family A. In the
same probands, a duplication of a CGCCCCA tandem-
repeat element, which normally is present in four copies
in intron 1, also was detected. The functional signifi-
cance of this intronic mutation is uncertain. Most mu-
tations were found in exon 9, where a 2-bp deletion
(845delCT) had occurred in three unrelated patients; in
one of them, the mutation was homozygous. The other
two index patients, in whom mutations were found on
both alleles, were compound heterozygotes for frame-
shift and splice mutations. Only a single heterozygous
mutation was found in three additional families.
The sequencing of exons 3–9 also revealed three ex-
onic polymorphisms, which were predicted to cause si-
lent substitutions (data not shown). Analysis of the
SURF-1 sequences in the probands’ parents was
consistent with the heterozygosity of the corresponding
mutations (data not shown).
Discussion
Strategies based on complementation by chromosome
transfer allow a genomewide screening of single index
cell lines. This is a distinct advantage for disorders, such
as LD(COX), for which the scarcity of informative fam-
ilies and the possibility of genetic heterogeneity can cause
linkage analysis to be difficult or not feasible.
In an initial series of experiments, not described in this
article, we tried to identify the chromosome containing
the complementing gene, by using microcell-mediated
chromosome transfer (MMCT) (Killary and Fournier
1995). MMCT allowed us to exclude two chromosomes
(2 and 5), but progress was frustratingly slow, because
of the unpredictability, laboriousness, and low efficiency
of this method, especially when the recipient cells were
slowly-growing fibroblasts, as in our study.
These factors prompted us to attempt a new strategy.
We first devised a method to eliminate endogenous
mtDNA from rodent cells or from rodent/human so-
matic cell hybrids. This goal was achieved by prolonged
exposure to high doses of EtBr, an intercalating agent
long used to create rho0 cell derivatives in different spe-
cies (King and Attardi 1989). We found that the con-
centration effective for the production of rodent rho0
cell lines was 100-fold higher than that used to produce
human rho0 cells, reflecting a remarkable metabolic re-
fractoriness of mtDNA in rodent species.
A prerequisite for the use of whole rodent/human rho0
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Table 3
SURF-1 Mutations in LD(COX) Patients
Patienta Mutation(s) Exon(s) Type(s) of Mutation
A 37ins17/37ins17 1/1 Frameshift/frameshift
B 5162TrG/550delAG 5/6 Splice/frameshift
C 868insT/868insT 9/9 Frameshift/frameshift
D 312del10,insAT/) 4/) Frameshift
E 845delCT/845delCT 9/9 Frameshift/frameshift
F 312del10,insAT/845delCT 4/9 Frameshift/frameshift
G 751CrT/751CrT 7/7 Stop/stop (Q251X)
H 845delCT/) 9/) Frameshift
I 772delCC/) 8/) Frameshift
a Patient designations are according to the corresponding family
designations shown in figure 6.
Figure 7 Mutation map and mutation detection by sequence analysis. Top, Examples of five SURF-1 mutations. Mutations 312del10,insAT
and 772delCC are heterozygous, whereas the remaining mutations are homozygous. For mutation 772delCC, the reverse complementary strand
is displayed. An asterisk (*) indicates the 751CrT transition. Mutations are numbered by considering the adenine of the first ATG of the SURF-
1 cDNA as nt position 1. Bottom, Genomic organization of SURF-1 and corresponding cDNA. The locations of the mutations along the
cDNA sequence are indicated.
somatic cell hybrids as donors of human chromosomes
was the inability of the rodent genome to either com-
plement or induce the enzyme defect. This was proved
in a series of experiments in which rodent rho0 cell lines
were PEG fused with either the LD(COX) SpBABE40 cell
line or with the control transformant ApBABE40 cell
line; the resulting hybrids consistently were COX defec-
tive in the former set of experiments, whereas they con-
sistently were COX positive in the latter.
After the EtBr treatment of the somatic cell hybrids,
the content of human chromosomes in the rho0 hybrid
derivatives was verified by FISH. No loss of human ge-
netic material was observed in any of the rodent/human
monochromosome hybrids that contained a selectable
marker inserted into the human chromosome. However,
hybrids lacking human-specific selectable markers, such
as the hamster/human hybrids containing different sets
of human chromosomes, underwent an apparently ran-
dom loss of human chromosomes, during the EtBr treat-
ment. Nevertheless, the use of human/rodent monochro-
mosome or of human/rodent polychromosome rho0
hybrid derivatives allowed us to conclude that most of
the human genome does not contain a COX-comple-
menting gene. Primary evidence of COX complemen-
tation was obtained from fusions between an LD(COX)
cell line and a hamster/human hybrid containing human
chromosome 9 only. Numerous foci of COX-positive
cells were detected, by COX-specific histochemistry, as
early as 4 d after fusion. This result was confirmed by
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histochemical and biochemical analyses of COX in the
heterodikaryon fusion cells.
With the limitations mentioned above, the method
presented here appears to offer several advantages over
MMCT. First, in the presence of a complementing chro-
mosome, all the heterodikaryon fusion cells, in principle,
should show complementation. Thus, starting with an
equal number of cocultured parental cells, if we assume
that fusions occur randomly, approximately one-third of
the fusion cells should show heterodikaryon comple-
mentation. These figures are in marked contrast with the
extremely low efficiency of MMCT, which typically is
reported to result in 0.5– “positive” clones55.0# 10
that survive after selection (Fournier 1981). Second, the
procedure is straightforward, and cell toxicity is low, in
contrast with the low efficiency, unpredictability, high
cell toxicity, and laboriousness of MMCT. Third, this
method allows a very rapid screening of the entire hu-
man genome, by using rodent/human hybrids containing
different panels of human chromosomes. For instance,
the lack of complementation in the cell fusions
performed between the LD(COX) SpBABE40 cell line
and the rho0rho0 derivatives Y.XY.8F6-r0, Hy137J-r0,
and Hy166T4-r0 suggested the absence of the respon-
sible gene in as many as 17 different human
chromosomes.
Linkage analysis of LD(COX) families belonging to the
same complementation group confirmed the localization
on chromosome 9 and indicated that the critical chro-
mosomal region for LD(COX) is flanked by markers
D9S1847 and D9S1826, which are located 7 cM apart
(see fig. 6). Interestingly, no genes encoding any protein
subunit of human COX have been mapped to this
region.
Three candidate genes encoding putative mitochon-
drial proteins (detected with the help of MITOP) were
mapped to the critical region. The first is the gene en-
coding endonuclease G, a protein believed to play a role
in mtDNA replication and transcription. The second is
a partial-length cDNA (KIAA0123) encoding a poly-
peptide related to the rat general mitochondrial MPP.
MPP is crucial in the processing of mitochondrial protein
precursors, by cleaving the N-terminal leader from the
mature protein. No mutations in either of these genes
were found in two LD(COX) patients. The third gene,
SURF-1, previously has been shown to be part of a
highly conserved “housekeeping” gene cluster, in several
mammalian (Lennard et al. 1994) and chicken (Co-
lombo et al. 1992) genomes. Although its precise func-
tion has not been determined, the SURF-1 protein prod-
uct likely is a mitochondrial protein affecting respiratory
function, including cytochrome c oxidase activity.
The yeast homologue of SURF-1, SHY-1, encodes a
mitochondrial inner-membrane protein, and a shy-1 null
mutant is defective in mitochondrial respiration, because
of reduced COX activity (Mashkevich et al. 1997).When
analyzed by MITOPROT, the human SURF-1 deduced
protein sequence gave a 99.7% probability of being a
mitochondrially targeted polypeptide, with a putative
cleavage site of the leader peptide between amino acids
44 and 45, according to the “R-2 rule” (Nakai and Ka-
nehisa 1995). The presence of a typical mitochondrial
import-signal sequence provides further evidence that
SURF-1 encodes a mitochondrial protein. Two potential
transmembrane domains are predicted, one on the N
terminus of the putative mature protein (amino acids
60–80) and the second on the C terminus (amino acids
271–291), suggesting that, as for the product of SHY-
1, the SURF-1 protein is located in the mitochondrial
inner membrane.
By sequence analysis of PCR-amplified exons, we
found that the probands of all nine families shown in
figure 6 harbored mutations of SURF-1. The eight dif-
ferent mutations detected are all deleterious mutations,
since they lead to premature stops or frameshifts or since
they affect the correct splicing of the gene transcript.
Two mutations were found in more than one family. The
first is a complex rearrangement consisting of a 10-bp
deletion encompassing nts 312–321 plus an insertion of
an AT doublet. This mutation, which creates a prema-
ture stop codon at nt 314, was found in a compound-
heterozygous state. The second mutation was a 2-bp
deletion at nts 845–846, producing a premature stop
codon at nt 867. This mutation was found in four chro-
mosomes (one homozygous and two compound heter-
ozygous patients). As was expected on the basis of family
history and haplotype reconstruction, the patients that
belonged to consanguinous families had homozygous
mutations (see table 3). Although not proved formally,
distant consanguineity between the parents of family G
is likely, since they both originated from a small, isolated
village in northern Appennines and since the surname
of several of their ancestors is the same. This could ex-
plain the presence of a homozygous mutation in the
affected child from this family.
Six LD(COX) patients had mutations on both SURF-1
alleles, whereas only a single mutation was found in
three patients. Mutations in intron sequences and other
regulatory sequences of SURF-1 or in exons that are
difficult to analyze, such as the GC-rich exons 1 and 2,
are predicted to account for the missing second mutation
in these patients.
The biochemical phenotype of all the patients inves-
tigated was homogeneous, since COX activity was re-
duced to ∼10% of the controls’ mean, in muscle and
fibroblast specimens from all patients. This homogeneity
can be explained by the type of the mutation, which
predicts the loss of function of the causative protein,
SURF-1.
Our results indicate that mutations of SURF-1 are
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responsible for at least one predominant complemen-
tation group of LD(COX). Although the mouse SURF-1
protein is 75% identical to the human polypeptide, the
rodent nuclear background did not rescue the COX phe-
notype in our fusions, suggesting a highly specific inter-
action between the product of SURF-1 and the respi-
ratory complex. Biochemical studies focused on the
respiratory-chain complexes in both yeast and mam-
malian systems will shed new light on the molecular
pathogenesis of this important mitochondrial disorder.
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